LITHICARB lithium carbonate 250mg tablet bottle

Quốc gia: Úc

Ngôn ngữ: Tiếng Anh

Nguồn: Department of Health (Therapeutic Goods Administration)

Thành phần hoạt chất:

lithium carbonate, Quantity: 250 mg

Sẵn có từ:

Aspen Pharmacare Australia Pty Ltd

Dạng dược phẩm:

Tablet, film coated

Thành phần:

Excipient Ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type A; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch

Tuyến hành chính:

Oral

Các đơn vị trong gói:

100, 200 tablets, 1000

Loại thuốc theo toa:

(S4) Prescription Only Medicine

Chỉ dẫn điều trị:

Mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. In recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. In some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. Those in the latter category who do respond have frequently had affective symptoms at some time. It is used in character or personality disorders in young people with clear evidence of cyclothymia. Lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. If the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considered. With three episodes in two years, there is no doubt it should be given. As a general rule, it should be prescribed, and therapeutic response assessed, satisfactory maintenance dosage determined, side and toxic effects and associated precautions discussed with the patient and relatives, and blood levels monitored, only under specialist supervision except perhaps in isolated areas. A major management problem also is that there are relatively narrow distances between the therapeutic and toxic dosages and blood levels. For these reasons treatment is preferably commenced on an inpatient basis, so that the patient is under appropriate observation.

Tóm tắt sản phẩm:

Visual Identification: White to off-white oval-shaped bevel edged film coated tablets with breakline on one side and plain on the other side.; Container Type: Bottle; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius

Tình trạng ủy quyền:

Licence status A

Ngày ủy quyền:

1994-07-21

Tờ rơi thông tin

LITHICARB
®
1
LITHICARB
®
_Lithium carbonate _
CONSUMER MEDICINE INFORMATION (CMI)
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Lithicarb. It does not
contain all the information that is
known about Lithicarb. It does not
take the place of talking to your
doctor or pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking Lithicarb
against the benefits they expect it
will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT LITHICARB IS USED
FOR
Lithicarb is used to both treat and
prevent episodes of a condition
called manic-depressive or bipolar
disorder, in which there are sustained
mood swings either up (manic) or
down (depression).
It is also used in the treatment of
schizo-affective illness and chronic
schizophrenia.
Lithicarb contains lithium (as lithium
carbonate) as the active ingredient.
Lithium is a powerful mood
stabiliser, however, the exact way
that lithium works to stabilise a
person's mood is not known. It helps
you to have more control over your
emotions and helps you cope better.
Your doctor, however, may have
prescribed Lithicarb for another
purpose.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY LITHICARB HAS
BEEN PRESCRIBED FOR YOU.
This medicine is available only with
a doctor's prescription.
There is no evidence that it is
addictive.
BEFORE YOU TAKE IT
_WHEN YOU MUST NOT TAKE IT _
DO NOT TAKE LITHICARB IF YOU HAVE
AN ALLERGY TO:
•
any medicine containing lithium
•
any of the ingredients listed at the
end of this leaflet.
Some of the symptoms of an allergic
reaction may include shortness of
breath, wheezing or difficulty
breathing; swelling of the face, lips,
tongue or other parts of the body;
rash, itching or hives on the skin.
DO NOT TAKE LITHICARB IF YOU HAVE
OR HAVE HAD:
•
severe heart or kidney disease
•
low activity of the adrenal gland
(e.g. Addison's disease)
•
an underactive thyroid g

Đặc tính sản phẩm

LITHICARB- Product Information
Page 1 of 10
AUSTRALIAN PRODUCT INFORMATION
LITHICARB
Lithium carbonate
1.NAME OF THE MEDICINE
lithium carbonate
2&3. QUALITATIVE AND QUANTITATIVE COMPOSITION AND
PHARMACEUTICAL FORM
White to off-white oval-shaped bevel edged film coated tablets, with
breakline on one
side and plain on the other side.
Each LITHICARB tablet contains 250 mg of the active lithium carbonate.
List of
excipients with known effect: lactose. For the full list of
excipients, see Section 6.1
List of excipients.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
The indications for lithium therapy may be summarised as follows:
It is given for mania, both as treatment and prophylaxis; manic
depressive (bipolar)
illness, both as treatment and as prophylaxis; it is less effective in
depressive
swings. In recurrent endogenous (unipolar) depressive illness, it is
highly effective
as prophylaxis in a number of cases, and is probably useful as
treatment, especially
if there is a family history of manic depressive illness and response
to lithium.
In some cases of schizo-affective illness and so called chronic
schizophrenia it is
dramatically effective. Those in the latter category who do respond
have frequently
had affective symptoms at some time. It is used in character or
personality disorders
in young people with clear evidence of cyclothymia.
Lithium should not be prescribed until it is certain that the manic
depressive swings
are established and the course of the disease certain. If the patient
has two effective
swings in one year, perhaps in opposite directions, and associated
with a positive
family history, it should certainly be seriously considered. With 3
episodes in two
years, there is no doubt it should be given. As a general rule, it
should be prescribed
and therapeutic response assessed, satisfactory maintenance dosage
determined,
side and toxic effects and associated precautions discussed with the
patient and
relatives
and
blood
levels
monitored,
only
under
specialist
supervision
except
perhaps in isol